AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06269523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping, Lymphatic drainage
Description: Kinesio tape, is an elastic cotton strip with an acrylic adhesive that is purported to ease pain and disability from athletic injuries and a variety of other physical disorders. The application of Kinesio Tex Tape facilitates the opening of microvalves due to a dynamic pressure variation due to alteration in skin density. This decompression activates lymphatics in the dermis and improves lymphatic flow. The end result is a tissue inflammation and swelling reduction.It has been applied at the end over every session after lymphatic dreinage (see below).
Study NCT06269523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lymphatic drainage
Description: Lymphatic drainage is a type of manual manipulation of the skin based on the hypothesis that it will encourage the natural drainage of the lymph, which carries waste products away from the tissues back toward the heart. The lymph system depends on intrinsic contractions of the smooth muscle cells in the walls of lymph vessels (peristalsis) and the movement of skeletal muscles to propel lymph through the vessels to lymph nodes and then to the lymph ducts, which return lymph to the cardiovascular system. Manual lymph drainage uses a specific amount of pressure and rhythmic circular movements to stimulate lymph flow.
Study NCT05902585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: In the virtual reality group, patients will view a video with the virtual reality glasses from the beginning to the end of the venipuncture.
Study NCT06059586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic health therapy
Description: Female Sexual Function Index (FSFI) and VAS Pain Scale Questionnaires, Physical Therapy Evaluation including Pelvic Floor Muscle Examination, Dilator Education
Study NCT06059586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilator feasability
Description: Patient Adherence to Vaginal Dilation Questionnaire
Study NCT05932732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HydraFacial Syndeo System
Description: Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.
Study NCT05932732 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ReGen-GF
Description: The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
Study NCT05703633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: uDCD treatment
Description: Thrombolytic treatment/prevention ex-vivo to kidneys procured from patients after circulatory arrest
Study NCT06396182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group (A ) study group :virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller).
Description: group (A ) study group : virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller):~The VR cycling session utilized the VZFIT VR Exercise Bike (VZFIT, Cambridge, MA), games were selected as preliminary pilot trials indicated these games to be most intense. Players maneuvered during VR gameplay by pedaling and steering their virtual character by leaning their bodies left and right. (Daniel et al., 2020).~group (B) control group :Cycling by traditional stationary bike: Participants will require to continuously pedal using the pulse oximeter for HR monitor. Research personnel monitored participants during the session adjusting pedal-resistance to ensure that the participants stayed within their target HR zone. (Daniel et al., 2020).
Study NCT06396182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group (A ) study group :virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller).
Description: group (A ) study group : virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller):~The VR cycling session utilized the VZFIT VR Exercise Bike (VZFIT, Cambridge, MA), games were selected as preliminary pilot trials indicated these games to be most intense. Players maneuvered during VR gameplay by pedaling and steering their virtual character by leaning their bodies left and right. (Daniel et al., 2020).~group (B) control group :Cycling by traditional stationary bike: Participants will require to continuously pedal using the pulse oximeter for HR monitor. Research personnel monitored participants during the session adjusting pedal-resistance to ensure that the participants stayed within their target HR zone. (Daniel et al., 2020).
Study NCT05409378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)
Description: Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation
Study NCT04998201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-APOC3
Description: ARO-APOC3 Injection
Study NCT04998201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Normal Saline (0.9% NaCl)
Study NCT02551952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MentalPlus®
Description: Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
Study NCT02551952 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MentalPlus®
Description: Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
Study NCT04405765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT and lyopreserved Stravix
Description: Subjects will be treated with NPWT and lyopreserved Stravix
Study NCT04405765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT and cryopreserved Stravix
Description: Subjects will be treated with NPWT and lyopreserved Stravix
Study NCT04849650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride IV
Description: A single 10mg IV dose of Amisulpride given over 1 minute
Study NCT04849650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride Oral Tablet
Description: A single 10mg dose given as an oral tablet
Study NCT05932732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HydraFacial Elite MD System
Description: Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.
Study NCT06467734 — intervention group
Intervention type: DEVICE
Intervention: Joint aspiration
Description: Joint puncture to extract joint fluid.
Study NCT06334198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naldemedine
Description: Naldemedine is administered orally once daily in the morning in a dosage of 0.2 mg.
Study NCT06334198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered orally once daily in the morning.
Study NCT06334198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: In both arms, tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200mg).
Study NCT06334198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: In both arms, tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200mg).
Study NCT05441904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: A single dose of 500 and 750 mg was administered to each subject.
Study NCT06201325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality based exercises
Description: play VR games
Study NCT06201325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: streching and strengthening exercises
Study NCT06201325 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: home exercises program
Description: home exercises
Study NCT06201325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercises program
Description: home exercises
Study NCT05272917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorial tests
Description: Patients will be included in the study between 3 to 6 months after the end of treatment and go to the Paul Bocuse Research Institute to perform several sensorial tests. The same sensorial tests will be completed by healthy volunteers to compare.
Study NCT05272917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensorial tests
Description: Patients will be included in the study between 3 to 6 months after the end of treatment and go to the Paul Bocuse Research Institute to perform several sensorial tests. The same sensorial tests will be completed by healthy volunteers to compare.
Study NCT05272917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: food preferences questionnaires
Description: Patients will be included in the study between 3 to 6 months after the end of treatment and go at Institut Paul Bocuse to complete food preferences questionnaires. The same questionnaires will be completed by healthy volunteers to compare.
Study NCT05272917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: food preferences questionnaires
Description: Patients will be included in the study between 3 to 6 months after the end of treatment and go at Institut Paul Bocuse to complete food preferences questionnaires. The same questionnaires will be completed by healthy volunteers to compare.
Study NCT03834298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Four Food Elimination Diet
Description: Food allergens are thought to initiate eosinophilic inflammation and dietary elimination of trigger allergens is an effective treatment for EoE. Previous work demonstrates that in both children and adult EoE patients, the food antigens including cow's milk, wheat, egg, soy, peanut/tree nut and fish/shell fish, are the most common food triggers causing esophageal inflammation. Participants will be assigned to single arm treatment / intervention with a diet restricted of the four most common food allergens, milk, soy, wheat and egg, or a four food elimination diet (FFED). With the goal to optimize diet treatment, in Aim 2, eligible participants will undergo sequential food reintroductions based on protocol.
Study NCT05658549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine dosage 600 mg and 1200 mg
Study NCT05658549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine dosage 600 mg and 1200 mg
Study NCT04194970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With WBM smart insole system to monitor compliance of specified weight bearing limits data in live feedback on and off situations
Description: Weight Bearing Protocol (Duration: Post-Op. 6 week)~* Post-op 3 week non-weight bearing (%0 body weight of patient)~* Post- op 3 week touch down weight bearing (%10-%20 body weight of patient) Group I - monitoring with device while the live feedback mechanism turned on Group II- monitoring with device while the live feedback mechanism turned off
Study NCT04194970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: With WBM smart insole system to monitor compliance of specified weight bearing limits data in live feedback on and off situations
Description: Weight Bearing Protocol (Duration: Post-Op. 6 week)~* Post-op 3 week non-weight bearing (%0 body weight of patient)~* Post- op 3 week touch down weight bearing (%10-%20 body weight of patient) Group I - monitoring with device while the live feedback mechanism turned on Group II- monitoring with device while the live feedback mechanism turned off
Study NCT02551952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MentalPlus®
Description: Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
Study NCT06101446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavander Aromatherapy
Description: Aromatherapy is one of the potential non-pharmacological methods. Lavender oil has been known to have calming properties and is one of the most effective aromatherapy oils. It reduces blood pressure and anxiety by stimulating the parasympathetic system
Study NCT06158139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9-CAR.B7-H3 T cell infusion
Description: iC9-CAR.B7-H3 T cell product will be administered via intravenous injection over 5 - 10 minutes.
Study NCT04879329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV; intravenous) every 2 weeks.
Study NCT04879329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Given by IV on Day 1 of each 6-week cycle.
Study NCT05733299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aflo™ digital respiratory management platform
Description: medical device, user app, clinician portal, data analytics hub
Study NCT05733299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Health service standard care will be continued
Study NCT05733299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Health service standard care will be continued
Study NCT06398405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate
Description: Epigallocatechin-3-gallate is administered in a solution with a concentration of 4400 umol/L
Study NCT06464159 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological collection
Description: A collection of maternal plasma, serum and urine
Study NCT06281613 — intervention group
Intervention type: DEVICE
Intervention: AMCOP group
Description: Patients were treated with AMCOP for 18 months.
Study NCT06281613 — intervention group
Intervention type: DEVICE
Intervention: High-pull headgear
Description: Patients were treated with high-pull headgear for 18 months.
Study NCT05573412 — intervention group
Intervention type: OTHER
Intervention: Cellular analysis
Description: Previously cryopreserved samples will be analyzed for total nucleated cell count (TNC), cell viability and proliferative potential
Study NCT04764266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heparansulfate and Syndecan 1
Description: Blood samples will be collected from the patient at 5 different time points. Three perfusate samples will be collected during normothermic machine perfusion (4,9ml each).
Study NCT05697978 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Monofocal intraocular lens Clareon (Alcon LLC)
Description: monofocal aspheric lens implanted in eyes of patient during routine cataract surgery
Study NCT04980326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doing What Matters (DWM)
Description: The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, will be adapted for use on a smartphone or other device with internet access during Phase 1 of RESPOND. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
Study NCT04980326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
Study NCT04980326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological First Aid (PFA)
Description: PFA is a brief intervention consisting of providing basic information for peer support in times of emotional distress
Study NCT04980326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological First Aid (PFA)
Description: PFA is a brief intervention consisting of providing basic information for peer support in times of emotional distress
Study NCT04907851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Study NCT04907851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
Study NCT04907851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Study NCT04907851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
Study NCT04907851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks
Study NCT06073990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTi)
Description: The intervention consists of four weeks of BBTi. During the first week, participants will receive face-to-face sleep assessments and sleep hygiene education. In the second week, a phone interview will be conducted to assess the patient's progress and provide appropriate relaxation techniques. Unsatisfactory responses to sleep restriction therapy or stimulation control methods will be addressed through face-to-face interviews in the third week. The fourth week will involve an overall review and evaluation conducted via a telephone interview.
Study NCT06022484 — intervention group
Intervention type: OTHER
Intervention: The present study does not contain any intervention
Description: The present study does not contain any intervention
Study NCT06520969 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prevelance of Uterine Vein and Uterine Vein System Variations (anatomical study)
Description: Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients